Ziopharm Oncology Inc. (ZIOP) Position Cut by Private Wealth Partners LLC
Private Wealth Partners LLC cut its position in shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) by 57.4% during the second quarter, Holdings Channel reports. The institutional investor owned 20,000 shares of the biotechnology company’s stock after selling 27,000 shares during the period. Private Wealth Partners LLC’s holdings in Ziopharm Oncology were worth $110,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the stock. Palo Capital Inc. acquired a new position in shares of Ziopharm Oncology during the second quarter worth approximately $350,000. Fox Run Management L.L.C. acquired a new position in shares of Ziopharm Oncology during the second quarter worth approximately $133,000. Creative Planning increased its position in shares of Ziopharm Oncology by 185.1% in the second quarter. Creative Planning now owns 30,864 shares of the biotechnology company’s stock worth $169,000 after buying an additional 20,040 shares in the last quarter. Royal Bank of Canada increased its position in shares of Ziopharm Oncology by 6.4% in the first quarter. Royal Bank of Canada now owns 16,189 shares of the biotechnology company’s stock worth $120,000 after buying an additional 974 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new position in shares of Ziopharm Oncology during the first quarter worth approximately $1,732,000. 44.95% of the stock is currently owned by institutional investors and hedge funds.
Shares of Ziopharm Oncology Inc. (NASDAQ:ZIOP) traded up 0.53% on Wednesday, reaching $5.67. 1,221,231 shares of the company’s stock traded hands. Ziopharm Oncology Inc. has a 52 week low of $4.45 and a 52 week high of $14.93. The firm’s market capitalization is $739.91 million. The company’s 50-day moving average is $5.48 and its 200-day moving average is $6.36.
Ziopharm Oncology (NASDAQ:ZIOP) last issued its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.90. Ziopharm Oncology had a negative return on equity of 100.01% and a negative net margin of 2,292.26%. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $1.52 million. During the same period in the prior year, the company earned ($0.11) EPS. The firm’s revenue was up 525.0% compared to the same quarter last year. Equities research analysts anticipate that Ziopharm Oncology Inc. will post ($1.34) earnings per share for the current fiscal year.
A number of brokerages have recently commented on ZIOP. Wells Fargo & Co. reissued a “sell” rating on shares of Ziopharm Oncology in a research note on Wednesday, June 8th. Griffin Securities reaffirmed a “buy” rating and set a $21.00 price target on shares of Ziopharm Oncology in a research note on Tuesday, June 7th. Zacks Investment Research raised shares of Ziopharm Oncology from a “hold” rating to a “buy” rating and set a $6.50 price target on the stock in a research note on Tuesday, August 16th. Finally, Mizuho reaffirmed a “neutral” rating and set a $5.00 price target (down previously from $7.00) on shares of Ziopharm Oncology in a research note on Monday, July 18th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Ziopharm Oncology presently has an average rating of “Buy” and a consensus price target of $9.75.
Ziopharm Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.
Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ziopharm Oncology Inc. (NASDAQ:ZIOP).
Receive News & Ratings for Ziopharm Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ziopharm Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.